HOUSE OF REPRESENTATIVES

H.B. NO.

1340

THIRTY-SECOND LEGISLATURE, 2023

H.D. 2

STATE OF HAWAII

 

 

 

 

 

 

A BILL FOR AN ACT

 

 

RELATING TO MENTAL HEALTH.

 

 

BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF HAWAII:

 


SECTION 1. The legislature finds that mental health conditions are treated in various ways, depending on the condition, and can include medication, therapy, and psychosocial services. Congress, through the Breakthrough Therapies Act, and the Food and Drug Administration has indicated that 3,4-methylenedioxymethamphetamine, commonly known as MDMA, and psilocybin will be rescheduled to enable therapeutic use. MDMA and psilocybin have already been granted the Food and Drug Administration's breakthrough therapy designation to fast-track research and potential approval given efficacy in treating treatment-resistant depression and post-traumatic stress disorder. These treatments, while effective for certain conditions and patients, do not treat all mental health conditions. However, research supports the effectiveness of natural and alternative medicines and therapies, such as the use of MDMA, psilocybin, and other therapies, as a safe and effective way to potentially treat depression, post-traumatic stress disorder, addiction, end-of-life psychological distress, and other afflictions.

The legislature further finds that the department of health should be empowered to review relevant laws, regulations, and studies each time a breakthrough therapy designation is issued to review any new treatment intended for mental health or substance abuse to prepare the State for the treatment's eventual approval by the federal Food and Drug Administration.

The purpose of this Act is to authorize the director of health to establish a temporary breakthrough therapy designations advisory council within three months of a breakthrough therapy designation approval by the Food and Drug Administration.

SECTION 2. Chapter 321, Hawaii Revised Statutes, is amended by adding a new section to part I to be appropriately designated and to read as follows:

"321-    Temporary breakthrough therapy designation advisory council. (a) The director of health may establish a temporary breakthrough therapy designation advisory council to assess a breakthrough therapy designation for a mental health or substance abuse treatment within three months of a breakthrough therapy designation approval by the United States Food and Drug Administration. The advisory council is established within the department of health for administrative purposes only.

(b) The advisory council shall consist of the following members or their designees:

(1) The director of health, who shall serve as the chairperson of the advisory council;

(2) The attorney general;

(3) The director of law enforcement;

(4) The chairpersons of the standing committees within the senate and house of representatives with primary jurisdiction over health;

(5) A physician who is duly licensed pursuant to chapter 453 or an advanced practice registered nurse who is authorized to prescribe psychotropic medication and is duly licensed pursuant to chapter 457; and

(6) Other members as recommended by the director of health, president of the senate, or speaker of the house of representatives, who represent relevant community, advocacy, or stakeholder interests.

(c) Members shall serve without compensation, but may be reimbursed for necessary expenses, including reasonable travel expenses, incurred in the performance of their duties.

(d) The advisory council shall:

(1) Examine federal and state laws, regulations, administrative rules, and community practices regarding the treatment of mental health or substance abuse conditions for which the breakthrough therapy designation applies;

(2) Examine available clinical and scientific studies, research, and other information relating to the safety and efficacy of methods to treat mental health or substance abuse conditions for which the breakthrough therapy designation applies;

(3) Examine requirements, specifications, and guidelines for a health care professional to prescribe and provide various treatments for patients who may benefit; and

(4) Submit a report of its findings and recommendations, including any proposed legislation, to the legislature no later than one year after the advisory council is convened.

(e) The advisory council may convene as necessary but shall terminate upon the withdrawal of the breakthrough therapy designation or final approval by the United States Food and Drug Administration.

(f) As used in this section, "breakthrough therapy designation" means a designation by the United States Food and Drug Administration, pursuant to the Food and Drug Administration Safety and Innovation Act (P.L. 112-144)."

SECTION 3. New statutory material is underscored.

SECTION 4. This Act shall take effect on June 30, 3000.


 


 

Report Title:

Temporary Breakthrough Therapy Designation Advisory Council; DOH; Mental Health

 

Description:

Authorizes the director of health to establish a temporary breakthrough therapy designation advisory council within three months of a breakthrough therapy designation approval by the United States Food and Drug Administration. Effective 6/30/3000. (HD2)

 

 

 

The summary description of legislation appearing on this page is for informational purposes only and is not legislation or evidence of legislative intent.